Research
Hormonal
Tirzepatide induces significant weight loss (up to 20.4% with 15mg dose) in individuals with overweight or obesity, comparable to effects observed with bariatric surgery.
For individuals with obesity, tirzepatide offers a non-surgical path to significant weight loss. In clinical trials, the highest dose resulted in an average loss of over 20% of body weight, which is comparable to the results typically seen with bariatric surgery. This makes it a powerful alternative for those who cannot undergo or prefer to avoid surgery.
StrongSupportsHIGH confidence
The use of tirzepatide once weekly provided substantial and sustained reductions in body weight in a dose-dependent manner from -15% with 5 mg reaching up to -20.4% weight change with 15 mg dose versus -3.1% in the placebo group [48]. These observations, especially with the high dose regimen, are comparable to effects observed with bariatric/metabolic surgery [48].
Why this rating
Based on SURMOUNT-1, a large Phase 3 RCT.
Source
The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity
Ioannis Lempesis et al. · Metabolism Open · 2022
narrative_reviewCited 26×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →